RECRUITING

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Talk to us

Conditions

Atopic Dermatitis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Official Title

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Quick Facts

Study Start:2025-07-14
Study Completion:2027-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06988605

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
  2. * Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
  3. * Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
  1. * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
  2. * Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
  3. * Participants who received nemolizumab previously.
  4. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Contacts and Locations

Study Contact

Galderma Research and Development
CONTACT
817-961-5000
clinical.studies@galderma.com

Study Locations (Sites)

Galderma Investigational Site - 8893
Birmingham, Alabama, 35244
United States
Galdrma Investigational Site - 7077
Phoenix, Arizona, 85006-2754
United States
Galderma Investigational Site 7060
Phoenix, Arizona, 85008-3884
United States
Galderma Investigational Site - 8535
Phoenix, Arizona, 85032-2238
United States
Galderma Investigational Site - 7067
Tucson, Arizona, 85718
United States
Galderma Investigational Site - 7074
Corona, California, 92882
United States
Galderma Investigational Site 6836
Fountain Valley, California, 92708-3701
United States
Galderma Investigational Site 8224
Fremont, California, 94538-1603
United States
Galderma Investigational Site 7100
Irvine, California, 92697
United States
Galderma Investigational Site 7099
Los Angeles, California, 90024-2801
United States
Galderma Investigational Site 8553
Newport Beach, California, 92663-3606
United States
Galderma Investigational Site 6836
San Francisco, California, 94115-3011
United States
Galderma Investigational Site
Santa Monica, California, 90404-2216
United States
Galderma Investigational Site 7107
Thousand Oaks, California, 91360-7746
United States
Galderma Investigational Site 7061
Castle Rock, Colorado, 80109-8034
United States
Galderma Investigational Site 7059
Fairfield, Connecticut, 76824
United States
Galderma Investigational Site 7105
Coral Gables, Florida, 33134-2073
United States
Galderma Investigational Site 7063
Cutler Bay, Florida, 33157
United States
Galderma Investigational Site 7101
Jupiter, Florida, 33477
United States
Galderma Investigational Site 7021
Miami, Florida, 33137
United States
Galderma Investigational Site 7084
Miami, Florida, 33173-3255
United States
Galderma Investigational Site 7078
Miami, Florida, 33173
United States
Galderma Investigational Site 7070
North Miami Beach, Florida, 33162-4708
United States
Galderma Investigational Site 7090
Saint Petersburg, Florida, 33713-8012
United States
Galderma Investigational Site 7054
Tampa, Florida, 33431-5133
United States
Galderma Investigational Site 7054
Tampa, Florida, 33609-2230
United States
Galderma Investigational Site 7091
Tampa, Florida, 33615-4537
United States
Galderma Investigational Site 7058
Chicago, Illinois, 60641
United States
Galderma Investigational Site 8142
Indianapolis, Indiana, 46250-2041
United States
Galderma Investigational Site 7083
West Lafayette, Indiana, 47906-1569
United States
Galderma Investigational Site 7098
Columbia, Maryland, 21045-2336
United States
Galderma Investigational Site 8012
Glenn Dale, Maryland, 20769-9182
United States
Galderma Investigational Site 7068
Rockville, Maryland, 20850-6243
United States
Galderma Investigational Site 7065
Brighton, Massachusetts, 02135
United States
Galderma Investigationa Site 7104
Milford, Massachusetts, 01757
United States
Galderma Investigational Site 7066
Auburn Hills, Michigan, 48326-3396
United States
Galderma Investigational Site 7071
Caledonia, Michigan, 49316-7478
United States
Galderma Investigational Site 7108
Grandville, Michigan, 49418
United States
Galderma Investigational Site 7072
Troy, Michigan, 48084-5260
United States
Galderma Investigational Site 7057
Lee's Summit, Missouri, 64064
United States
Galderma Investigational Site 7076
Saint Louis, Missouri, 63141-7068
United States
Galderma Investigational Site 8848
Las Vegas, Nevada, 89144-0518
United States
Galderma Investigational Site 7055
Portsmouth, New Hampshire, 03801-7156
United States
Galderma Investigational Site - Site 7080
Auburn, New York, 13021
United States
Galderma Investigational Site # 7052
East Syracuse, New York, 13057
United States
Galderma Investigational Site - 8282
Mount Kisco, New York, 10549-3035
United States
Galderma Investigational Site - 7051
New York, New York, 10023
United States
Galderma Investigational Site 7109
New York, New York, 10028
United States
Galderma Investigational Site 8279
New York, New York, 10075-0337
United States
Galderma Investigational Site 7081
Dayton, Ohio, 45414-2799
United States
Galderma Investigational Site 7073
Gresham, Oregon, 97030-2923
United States
Galderma Investigational Site 8559
Philadelphia, Pennsylvania, 19103-4738
United States
Galderma Investigational Site 7103
Philadelphia, Pennsylvania, 19104
United States
Galderma Investigational Site 7106
Bluffton, South Carolina, 29910
United States
Galderma Investigational Site 7082
Cedar Park, Texas, 78613-7875
United States
Galderma Investigational Site 8238
Dallas, Texas, 75230-5808
United States
Galderma Investigational Site 7062
Edinburg, Texas, 78539-4660
United States
Galderma Investigational Site 7088
Grapevine, Texas, 76051
United States
Galderma Investigational Site 7102
Houston, Texas, 77004-8098
United States
Galderma Investigational Site 7069
Sugar Land, Texas, 77478-3842
United States
Galderma Investigational Site 8618
Waco, Texas, 76710-4023
United States
Galderma Investigational Site 7085
Bountiful, Utah, 84010-4801
United States
Galderma Investigational Site 7079
Vienna, Virginia, 22182
United States

Collaborators and Investigators

Sponsor: Galderma R&D

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-14
Study Completion Date2027-11-30

Study Record Updates

Study Start Date2025-07-14
Study Completion Date2027-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Atopic Dermatitis